Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06396403
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:08.128339+00:00
Published At
2024-11-15T00:00:00+00:00
Record Updated At
2024-11-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Sickle Cell Retinopathy", "Sickle Cell Disease", "Sickle Cell SC Disease", "Sickle Cell-SS Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-11-15"
protocolSection.identificationModule.nctId
"NCT06396403"
protocolSection.identificationModule.officialTitle
"The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Sickle Cell Retinopathy (protocolSection.conditionsModule.conditions)
  • Sickle Cell Disease (protocolSection.conditionsModule.conditions)
  • Sickle Cell SC Disease (protocolSection.conditionsModule.conditions)
  • Sickle Cell-SS Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.